Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

AbbVie/Allergan’s merger faces public opposition

Advocacy groups and unions in the US express concerns

- PMLiVE

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects

- PMLiVE

AbbVie scores FDA approval for arthritis treatment upadacitinib

Could find it difficult to live up to Humira

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

Myovant has second phase 3 trial to back its uterine fibroids drug

Aims to take on AbbVie in new market

- PMLiVE

AbbVie cures STING fever with Mavupharma acquisition

Joins host of companies pursuing novel mechanism

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links